NCT01133301View on ClinicalTrials.gov

Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 1998

Primary Completion Date

August 31, 2001

Study Completion Date

October 31, 2001

Conditions
Borderline Personality DisorderDissociation
Interventions
DRUG

Naltrexone

50 mg/d Naltrexone will be administrated during three weeks.

DRUG

Placebo

During 3 weeks of the study, Placebo will be administrated (daily)

Trial Locations (1)

79104

Department of Psychiatry and Psychotherapy, University of Freiburg, Freiburg im Breisgau

All Listed Sponsors
collaborator

University of Freiburg

OTHER

lead

Central Institute of Mental Health, Mannheim

OTHER

NCT01133301 - Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder | Biotech Hunter | Biotech Hunter